-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $57

Benzinga·04/29/2026 15:01:39
Listen to the news
Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $53 to $57.